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po the Editor: Coronary flow reserve (CFR) is impaired in
atients with idiopathic dilated cardiomyopathy (IDC), despite
ngiographically normal coronary arteries, because of coronary
icrocirculatory dysfunction (1,2). Furthermore, it has been re-
orted that a decreased hyperemic response of coronary flow is an
ndicator of a poor prognosis in patients with idiopathic left
entricular (LV) dysfunction (3). This suggests that the restoration
f coronary microcirculation may lead to favorable clinical out-
omes in IDC patients.
Large clinical trials have demonstrated that carvedilol, a third-
eneration beta-adrenergic blocking agent endowed with vasodi-
ator and antioxidant properties, reduces morbidity and mortality
n patients with heart failure and LV dysfunction, including that
aused by IDC (4). However, the mechanisms behind the reduc-
ion of mortality in patients with IDC by carvedilol treatment
emain unclear. Carvedilol treatment may contribute to a reduction
f mortality in patients with IDC by improving CFR. The purpose
f this study was to evaluate the short- and long-term effects of
dministration of carvedilol on CFR, which reflects coronary
irculation, as assessed by transthoracic Doppler echocardiography
TTDE) in patients with IDC.
We studied 12 patients with IDC (8 men, 4 women; mean age
7  16 years) who had not taken beta-blockers. All patients had
linically stable New York Heart Association (NYHA) functional
lass I/II symptoms. Each patient enrolled in the study met the
ollowing criteria: 1) normal sinus rhythm; 2) normal coronary
rteries confirmed by coronary angiography or thallium-201
ingle-photon emission computed tomography; and 3) a LV
jection fraction (EF) 40%. Patients were excluded from the
tudy if they had primary valvular heart disease or any known cause
f dilated cardiomyopathy. All patients were stabilized using an
ngiotensin-converting enzyme inhibitor, angiotensin II receptor
locker, and diuretic treatment. Each patient received carvedilol in
ddition to their usual medications for heart failure. The starting
ose of carvedilol was 2.5 or 5.0 mg/day, which was then gradually
ncreased to a target dose of 20 mg/day or to a tolerated dose. An
chocardiographic examination was performed at baseline, one
onth, and six months during treatment with carvedilol. In-
ormed, written consent was obtained from each patient.
We used the Sequoia digital ultrasonography system (Siemens,
ountain View, California) or the Vivid 7 digital ultrasonography
ystem (GE Vingmed Ultrasound, Horten, Norway) for echocar-
iographic measurements. The LV end-diastolic volume, end-
ystolic volume, and EF were calculated using the biplane Simpson
ormula. The mitral inflow velocity wave was recorded by pulsed
oppler echocardiography, and the E-wave velocity, A-wave
elocity, E/A ratio and E-wave deceleration times were measured.
easurements of CFR in the left anterior descending coronary
rtery (LAD) by TTDE were performed as previously described
5), using high-frequency transducers (5.0- to 7.5-MHz on the
equoia digital ultrasonography system or 4.4- to 11.4-MHz on
he Vivid 7 digital ultrasonography system). We first recorded a maseline spectral Doppler signal in the LAD. Adenosine triphos-
hate was then administered intravenously (0.14 mg/kg body
eight/min) for 2 min to record the spectral Doppler signal of
eak flow response induced by dilation of the coronary microves-
els. In the serial studies, we tried to record the spectral Doppler
ignal of LAD flow at the same portion of the artery in the same
atient. All studies were acquired and stored digitally in the
ltrasound system for off-line analysis. Mean diastolic coronary
ow velocity (CFV) was measured by tracing the contour of the
pectral Doppler signal at baseline and at peak flow response. The
efinition of CFR was the ratio of mean CFV at peak flow
esponse to mean CFV at baseline.
The Friedman test was used to compare the three time points,
nd the Wilcoxon signed-rank test was performed if significance
as found. All tests were two-tailed. A value of p  0.05 was
ccepted as statistically significant. The quoted p values in Table 1
nd Figure 1 were derived from the Wilcoxon signed-rank test.
Of the 12 patients enrolled in this study, 2 did not complete the
tudy protocol. One patient discontinued carvedilol due to hypo-
ension and one died during follow-up. The mean maintenance
ose of carvedilol was 14  7 mg/day.
Hemodynamics and echocardiographic measurements are
hown in Table 1. Systolic and diastolic blood pressures were
ignificantly reduced at one month, but the change was not
tatistically significant at six months. Heart rate and the rate-
ressure product were significantly decreased at one month, with
o further change at six months. At one month, there was no
ignificant change in LV end-diastolic volume, whereas the LV
nd-systolic volume decreased significantly. At six months, a
ignificant reduction in both end-diastolic and -systolic volume
as observed. Although LVEF did not change at one month, it
ncreased significantly at six months. No significant changes were
bserved in the E- or A-wave velocity or E/A ratio at one or six
onths. The E-wave deceleration time increased significantly at
ne and six months.
Coronary flow data are shown in Figure 1. Resting CFV
emained unchanged at one month (22  6 cm/s) and at six
onths (21  5 cm/s), as compared with baseline (24  6 cm/s).
significant increase in adenosine-induced peak CFV was ob-
erved at one month (60  21 cm/s vs. 75  15 cm/s; p  0.05)
nd at six months (78  21 cm/s; p  0.05). The CFR increased
ignificantly at one month (2.6 0.9 vs. 3.5 0.7; p 0.05), and
his increase was confirmed at six months (3.7  0.6; p  0.05).
Previous studies reported that CFR was improved by an acute
ffect of beta-blockers in patients with coronary heart disease and
ealthy volunteers (6,7). In the present study, we observed that
FR in IDC patients was improved after both short- and
ong-term administration of carvedilol.
Therapeutic interventions could affect CFR by changing resting
r peak coronary flow. It has been reported that the increase of
eak CFV, rather than the decrease of resting CFV, may be of
ajor importance in improved CFR after beta-blocker treatment
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January 18, 2005:318–286,7). Resting coronary flow is determined by myocardial oxygen
emand (6,8). An acute effect of beta-blockers decreases myocar-
ial oxygen demand by reduced myocardial contractility and work,
ossibly leading to a reduction of resting coronary flow. However,
he autoregulation for coronary circulation may work to preserve
esting coronary flow volume within the autoregulatory range of
oronary perfusion pressure (8). The mechanisms of the increase in
eak coronary flow after carvedilol therapy are not fully defined.
ne possibility is that the action of beta-adrenergic blockade may
ecrease coronary vascular resistance by a diminution of the
xtravascular compressive forces, due to a reduced LV filling
ressure (6,7). Second, the blunted heart rate response during
eta-blockade may have beneficially affected the diastolic phase of
yocardial perfusion during hyperemia (6). Third, the alpha1-
drenergic blocking action of carvedilol may induce the additional
asodilation of the coronary microcirculation by blockade of
igure 1. The time course of change in coronary flow velocity (CFV) and
able 1. Hemodynamics and Echocardiographic Measurements
Baseline One Month Six Months
BP (mm Hg)
Rest 110 11 103 10* 107  11
Adenosine 107  8 101 9* 104  12
BP (mm Hg)
Rest 70  8 63 7* 66  9
Adenosine 67  9 62 4* 63  9
R (beats/min)
Rest 86  8 68 7* 69  9*
Adenosine 89  9 74 7* 75  9*
PP (beats/min 
mm Hg)
Rest 9,374 1,036 6,997 761* 7,388 747*
Adenosine 9,510 1,117 7,417 784* 7,752  1,223*
DV (ml) 208 47 189 46 162  52*
SV (ml) 152  45 131 41* 102  47*
F (%) 28  7 32 7 39  9*
-wave (cm/s) 73  24 59 23 53  17
-wave (cm/s) 70  30 68 25 78  16
/A ratio 1.4 1.2 1.0 0.7 0.7 0.2
T (ms) 148 66 209 58* 233  60*
p  0.05 vs. baseline. Data are presented as the mean value  SD.
DBP  diastolic blood pressure; DT  E-wave deceleration time; EDV 
nd-diastolic volume; EF  ejection fraction; ESV  end-systolic volume; HR 
eart rate; RPP  rate–pressure product; SBP  systolic blood pressure.oronary flow reserve (CFR) during carvedilol therapy. *p  0.05 vs.
aseline.lpha1-mediated coronary vasoconstrictor tone during hyperemia
9).
Transthoracic Doppler echocardiography provides noninvasive,
ccurate, and repeatable CFR measurements (5). We describe the
ime course of change in CFR affected by carvedilol therapy in
atients with IDC. In this study, LVEF improved significantly
fter six months of treatment, but there was no statistically
ignificant change in EF at one-month follow-up, despite a rapid
ncrease in CFR. Thus, the improvement of CFR is attained
efore improvement of LV systolic function, suggesting an early
ecovery of the coronary circulation in IDC patients by carvedilol
herapy, followed by improved LV systolic function.
The administration of carvedilol improves impaired CFR in
DC patients. These data indicate that the improvement in CFR
ay be one of the mechanisms by which carvedilol has a favorable
ffect on the prognosis in IDC patients. Furthermore, carvedilol
herapy improves CFR earlier than it does LV dysfunction in IDC
atients.
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